Negotiation, Pharmaceutical and Valuation

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

How2Exit

MARCH 31, 2024

With a career spanning over a decade, Patrick has become an industry-agnostic specialist, facilitating financial diligence, quality of earnings, purchase price negotiation, and offering comprehensive partnership support to his clients. rn rn rn Emotional readiness and concessions are critical in M&A transactions.

Business

Business Mergers and Acquisitions Securities M&A

What is Freight on Board (FOB)? Origin vs. Destination

Peak Frameworks

SEPTEMBER 18, 2023

company like Tesla, understanding terms like FOB is crucial when negotiating deals and supply contracts overseas. Consider a pharmaceutical giant like Pfizer , which imports raw materials for its drugs. The Importance of FOB for Financial Professionals Valuation Considerations FOB can directly impact the valuation of goods.

Private Equity

Private Equity Negotiation Transportation Valuation

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

SEPTEMBER 19, 2023

company to hit a $1 trillion valuation , it directly benefited shareholders. This deep involvement requires them to understand: Shareholder Interests: To gauge the return on investment and determine the valuation of potential deals. Shareholders: are primarily concerned about financial returns.

Corporation

Corporation Private Equity Mergers and Acquisitions Corporate Finance

The Cooley Outlook for 2018 M&A

Cooley M&A

FEBRUARY 8, 2018

Approval of gross-ups in connection with a transaction typically involves a prior negotiation with the buyer. Nevertheless, as gross-up arrangements are typically negotiated after the deal price is negotiated, we do not believe that these arrangements are impacting overall stockholder consideration.

M&A

M&A Mergers and Acquisitions Mergers Negotiation

The SaaS Prescription: Healthcare Trends and M&A Insights

Software Equity Group

JANUARY 22, 2024

Urgency Drives Healthy M&A Valuations Beyond the standard financial metrics that typically create valuations in any industry, the healthcare sector has several distinctive elements that significantly contribute to its valuation dynamics. Click here to fill out our assessment form.

Healthcare

Healthcare M&A Valuation Medical

The SaaS Prescription: Healthcare Trends and M&A Insights

Software Equity Group

JANUARY 22, 2024

Urgency Drives Healthy M&A Valuations Beyond the standard financial metrics that typically create valuations in any industry, the healthcare sector has several distinctive elements that significantly contribute to its valuation dynamics. Click here to fill out our assessment form.

Healthcare

Healthcare M&A Valuation Medical

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley M&A

OCTOBER 29, 2018

In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 The Merger Agreement.

Mergers and Acquisitions

Mergers and Acquisitions Mergers Business Pharmaceutical

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

From Mergers to Acquisitions: How to Successfully Execute a Corporate Restructuring Plan

Devensoft

MAY 25, 2023

From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan. For instance, a pharmaceutical company may acquire a smaller biotech firm to gain access to its research and development pipeline. 

Corporation

Corporation Mergers Mergers and Acquisitions Acquisitions

Monetizing an Earn-Out – Does That Make It a “Security?”

Cooley M&A

JULY 10, 2017

However, where there are too many unaccredited investors, parties may be unwilling or unable to pay the present cash value of the future earn-outs to the unaccredited investors (which would require a valuation of the future earn-outs). acquisitions of pharmaceutical products with clinical, regulatory and/or net sales milestones).

Securities

Securities IT Investors M&A

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A

M&A Mergers and Acquisitions Pharmaceutical Mergers

2017 M&A Trends Series: Cautious Optimism in the New Year

Cooley M&A

FEBRUARY 15, 2017

After some highly anticipated IPOs in the first half of 2017, we expect the reopening of capital markets in the latter half of the year to provide more stabilized valuations for companies, which should lead to more normalcy in M&A and strategic combinations. Negotiating Anti-Reliance Language. Innovation Pressures Fuel M&A.

M&A

M&A IPO Pharmaceutical Valuation

Investment Banking Today

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

What is Freight on Board (FOB)? Origin vs. Destination

Trending Sources

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

The Cooley Outlook for 2018 M&A

The SaaS Prescription: Healthcare Trends and M&A Insights

The SaaS Prescription: Healthcare Trends and M&A Insights

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley’s 2022 Life Sciences M&A Year in Review

From Mergers to Acquisitions: How to Successfully Execute a Corporate Restructuring Plan

Monetizing an Earn-Out – Does That Make It a “Security?”

Cooley’s 2021 Life Sciences M&A Year in Review

2017 M&A Trends Series: Cautious Optimism in the New Year

Stay Connected